{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:15:49Z","timestamp":1782803749629,"version":"3.54.5"},"reference-count":71,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Given the shortcomings of current factor-, nonfactor-, and adeno-associated virus gene\u2013based therapies, the recent advent of RNA-based therapeutics for hemophilia is changing the fundamental approach to hemophilia management. From small interfering RNA therapeutics that knockdown clot regulators antithrombin, protein S, and heparin cofactor II, to CRISPR\/Cas9 gene editing that may personalize treatment, improved technologies have the potential to reduce bleeds and factor use and avoid inhibitor formation. These novel agents, some in preclinical studies and others in early phase trials, have the potential to simplify treatment and improve hemostasis and quality of life. Furthermore, because these therapies arise from manipulation of the coagulation cascade and thrombin generation and its regulation, they will enhance our understanding of hemostasis and thrombosis and ultimately lead to better therapies for children and adults with inherited bleeding disorders. What does the future hold? With the development of novel preclinical technologies at the bench, there will be fewer joint bleeds, debilitating joint disease, orthopedic surgery, and improved physical and mental health, which were not previously possible. In this review, we identify current limitations of treatment and progress in the development of novel RNA therapeutics, including messenger RNA nanoparticle delivery and gene editing for the treatment of hemophilia.<\/jats:p>","DOI":"10.1182\/blood.2022018661","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T20:11:05Z","timestamp":1689970265000},"page":"1613-1621","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Innovations in RNA therapy for hemophilia"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5379","authenticated-orcid":false,"given":"Margaret V.","family":"Ragni","sequence":"first","affiliation":[{"name":"1Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Hemophilia Center of Western Pennsylvania, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-7527","authenticated-orcid":false,"given":"Stephen Y.","family":"Chan","sequence":"additional","affiliation":[{"name":"2Division of Cardiology, Department of Medicine, Vascular Medicine Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"suppl 6","key":"2023110916245186700_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"2023110916245186700_bib2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.hoc.2021.07.006","article-title":"Hemophilia A: factor VIII deficiency","volume":"35","author":"Seaman","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"2023110916245186700_bib3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"4","key":"2023110916245186700_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023110916245186700_bib5a","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023110916245186700_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023110916245186700_bib7","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/S2352-3026(19)30070-5","article-title":"The effect of emicizumab regimen on hemophilia outcomes","volume":"6","author":"Ragni","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"2023110916245186700_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18103\/mra.v9i11.2579","article-title":"Thrombosis complicating non-factor therapy for hemophilia","volume":"9","author":"Ragni","year":"2021","journal-title":"Med Res Arch"},{"issue":"8","key":"2023110916245186700_bib9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctogene roxaparvovec gene therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023110916245186700_bib10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6563","key":"2023110916245186700_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1126\/science.abg0856","article-title":"Hemophilia as a blueprint for gene therapy","volume":"374","author":"Ragni","year":"2021","journal-title":"Science"},{"issue":"4","key":"2023110916245186700_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2141.2007.06693.x","article-title":"Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients","volume":"138","author":"Shetty","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"2023110916245186700_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0029-1222609","article-title":"Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia","volume":"35","author":"Franchini","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"6669","key":"2023110916245186700_bib14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"6996","key":"2023110916245186700_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/430161a","article-title":"The RNAi revolution","volume":"430","author":"Novina","year":"2004","journal-title":"Nature"},{"issue":"6","key":"2023110916245186700_bib16","first-page":"421","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev"},{"key":"2023110916245186700_bib17","doi-asserted-by":"crossref","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: Mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2023110916245186700_bib18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A\u00a0molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol Ther"},{"key":"2023110916245186700_bib19","doi-asserted-by":"crossref","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"2023110916245186700_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJMcibr1505657","article-title":"Targeting antithrombin to treat hemophilia","volume":"373","author":"Ragni","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023110916245186700_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"issue":"9","key":"2023110916245186700_bib22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Phase I study of fitusiran, an RNAi therapeutic targeting antithrombin in hemophilia A or B","volume":"377","author":"Pasi","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023110916245186700_bib23","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran: results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10386","key":"2023110916245186700_bib24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomized phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"2023110916245186700_bib25","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"issue":"S1","key":"2023110916245186700_bib26","first-page":"40","article-title":"Consumption of on-demand factor concentrates and bypassing agents for management of breakthrough bleeds with fitusiran prophylaxis in people with haemophilia A or B: an analysis of two phase 3 studies","volume":"6","author":"Srivastava","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"S1","key":"2023110916245186700_bib27","first-page":"1152","article-title":"Fitusiran, an investigational siRNA therapeutic targeting antithrombin: analysis of antithrombin levels and thrombin generation from a phase 3 study in people with hemophilia A or B with inhibitors","volume":"6","author":"Rangarajan","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"S2","key":"2023110916245186700_bib28","first-page":"67","article-title":"Perioperative management of patients with hemophilia receiving fitusiran prophylaxis","volume":"4","author":"Ragni","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2023110916245186700_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"2023110916245186700_bib30","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1093\/nar\/gkac539","article-title":"From bench to bedside: improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization","volume":"50","author":"Schlegel","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"S2","key":"2023110916245186700_bib31","first-page":"56","article-title":"Fitusiran, an siRNA therapeutic targeting antithrombin for the treatment of hemophilia: proposed revisions to dose and regimen as a risk mitigation for vascular thrombosis","volume":"4","author":"Negrier","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"18","key":"2023110916245186700_bib32","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1182\/bloodadvances.2021004802C","article-title":"Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding","volume":"5","author":"Hoffman","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2023110916245186700_bib33","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/jth.13665","article-title":"Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitors, and protein S","volume":"15","author":"Dahlb\u00e4ck","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2023110916245186700_bib34","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1182\/blood.V64.6.1297.1297","article-title":"Plasma protein S deficiency in familial thrombotic disease","volume":"64","author":"Schwarz","year":"1984","journal-title":"Blood"},{"issue":"12","key":"2023110916245186700_bib35","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2017-09-800326","article-title":"Targeting anticoagulant protein S to improve hemostasis in hemophilia","volume":"131","author":"Prince","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2023110916245186700_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-138692","article-title":"Targeting protein S using small interfering RNA is well tolerated and protects mice with hemophilia A from acute hemarthrosis [abstract]","volume":"136","author":"Prince","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2023110916245186700_bib37","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood-2022-169029","article-title":"SLN140 a small interfering RNA targeting protein S improves hemostasis potency in hemophilia [abstract]","volume":"140","author":"Prince","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2023110916245186700_bib38","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/S0021-9258(19)83650-5","article-title":"The protease specificity of heparin cofactor II. inhibition of thrombin generation during coagulation","volume":"260","author":"Parker","year":"1985","journal-title":"J\u00a0Biol Chem"},{"issue":"8452","key":"2023110916245186700_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(85)92736-9","article-title":"Association of hereditary heparin co-factor II with thrombosis","volume":"2","author":"Tran","year":"1985","journal-title":"Lancet"},{"issue":"2","key":"2023110916245186700_bib40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1172\/JCI0213432","article-title":"Heparin cofactor II inhibits arterial thrombosis after endothelial injury","volume":"109","author":"He","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"2023110916245186700_bib41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.omtn.2021.03.022","article-title":"RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A","volume":"24","author":"Lin","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7841","key":"2023110916245186700_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/d41586-021-00019-w","article-title":"How COVID unlocked the power of RNA","volume":"589","author":"Dolgin","year":"2021","journal-title":"Nature"},{"issue":"10","key":"2023110916245186700_bib43","first-page":"E1941","article-title":"Systemic delivery of factor IX messenger RNA for protein replacement therapy","volume":"114","author":"Ramaswamy","year":"2017","journal-title":"Proc\u00a0Natl Acad Sci"},{"issue":"4","key":"2023110916245186700_bib44","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2018.210583","article-title":"Correction of bleeding in experimental severe hemophilia A by systemic delivery for factor VIII-encoding mRNA","volume":"105","author":"Russick","year":"2020","journal-title":"Haematologica"},{"key":"2023110916245186700_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","article-title":"Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles","volume":"20","author":"Chen","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"issue":"suppl 1","key":"2023110916245186700_bib46","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood-2022-167919","article-title":"Sustained factor VIII activity following single dose of non-viral integrating gene therapy [abstract]","volume":"140","author":"Truong","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2023110916245186700_bib47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrg3686","article-title":"A\u00a0guide to genome engineering with programmable nucleases","volume":"15","author":"Kim","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"7794","key":"2023110916245186700_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"issue":"7355","key":"2023110916245186700_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature10177","article-title":"In\u00a0vivo genome editing restores hemostasis in a mouse model of haemophilia","volume":"475","author":"Li","year":"2011","journal-title":"Nature"},{"issue":"19","key":"2023110916245186700_bib50","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1182\/blood-2013-04-497354","article-title":"Robust ZFN-mediated genome editing in adult hemophilic mice","volume":"122","author":"Anguela","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023110916245186700_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13287-018-0839-8","article-title":"Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system","volume":"9","author":"Lyu","year":"2018","journal-title":"Stem Cell Res Therapy"},{"issue":"5","key":"2023110916245186700_bib52","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.celrep.2018.03.121","article-title":"Autologous and heterologous cell therapy for hemophilia B toward functional restoration of factor IX","volume":"23","author":"Ramaswamy","year":"2018","journal-title":"Cell Rep"},{"issue":"2","key":"2023110916245186700_bib53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12185-019-02765-0","article-title":"CRISPR\/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs","volume":"111","author":"Morishige","year":"2020","journal-title":"Int J Hematol"},{"issue":"26","key":"2023110916245186700_bib54","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.2019000790","article-title":"CRISPR\/Cas9-mediated in\u00a0vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice","volume":"133","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"2023110916245186700_bib55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2019.02.009","article-title":"Long-term correction of hemophilia B using adenoviral delivery of CRISPR\/Cas9","volume":"298","author":"Stephens","year":"2019","journal-title":"J\u00a0Control Release"},{"issue":"1","key":"2023110916245186700_bib56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s13287-022-03036-2","article-title":"Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR\/Cas9 technology","volume":"13","author":"Ma","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"2023110916245186700_bib57","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.omtn.2022.08.002","article-title":"Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia","volume":"29","author":"Lee","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"2023110916245186700_bib58","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1038\/s41467-022-34898-y","article-title":"Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response","volume":"13","author":"He","year":"2022","journal-title":"Nat Commun"},{"issue":"15","key":"2023110916245186700_bib59","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In\u00a0vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2023110916245186700_bib60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stem.2015.07.001","article-title":"Functional correction of large FVIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9","volume":"17","author":"Park","year":"2015","journal-title":"Cell Stem Cell"},{"key":"2023110916245186700_bib61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtn.2019.05.019","article-title":"ssODN-mediated in-frame deletion with CRISPR\/Cas9 restores FVIII function in hemophilia A patient-derived iPSCs and ECs","volume":"17","author":"Hu","year":"2019","journal-title":"Mol Ther Nucleic Acid"},{"issue":"6","key":"2023110916245186700_bib62","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.stemcr.2019.04.016","article-title":"Universal correction of blood coagulation factor VIII in patient-derived induced pluripotent stem cells using CRISPR\/Cas9","volume":"12","author":"Park","year":"2019","journal-title":"Stem Cell Rep"},{"issue":"4","key":"2023110916245186700_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0243-1","article-title":"Restoration of FVIIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs","volume":"51","author":"Sung","year":"2019","journal-title":"Exp Mol Med"},{"issue":"1","key":"2023110916245186700_bib64","doi-asserted-by":"crossref","first-page":"16838","DOI":"10.1038\/s41598-019-53198-y","article-title":"Hemophilia A meliorated in mice by CRISPR-based in\u00a0vivo genome editing of human factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"2023110916245186700_bib65","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13059-019-1907-9","article-title":"Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse","volume":"20","author":"Zhang","year":"2019","journal-title":"Genome Biol"},{"issue":"S2","key":"2023110916245186700_bib66","first-page":"PB0656","article-title":"Targeted CRISPR\/Cas9-mediated gene addition to a safe harbor in placental cells for the treatment of hemophilia A","volume":"5","author":"Ramamurthy","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2023110916245186700_bib67","doi-asserted-by":"crossref","first-page":"672564","DOI":"10.3389\/fcell.2021.672564","article-title":"CRISPR\/Cas9-mediated in\u00a0vivo genetic correction in a mouse model of hemophilia A","volume":"9","author":"Luo","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2023110916245186700_bib68","doi-asserted-by":"crossref","first-page":"1115831","DOI":"10.3389\/fgene.2023.1115831","article-title":"Correction of F8 intron 1 inversion in hemophilia A patient- specific iPSCs by CRISPR\/Cas9 mediated gene editing","volume":"14","author":"Hu","year":"2023","journal-title":"Front Genet"},{"issue":"7785","key":"2023110916245186700_bib69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"5","key":"2023110916245186700_bib70","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","article-title":"Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing","volume":"40","author":"Anzalone","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2023110916245186700_bib71","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat Rev Genet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/19\/1613\/2088468\/blood_bld-2022-018661-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/19\/1613\/2088468\/blood_bld-2022-018661-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:25:43Z","timestamp":1699547143000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/19\/1613\/497007\/Innovations-in-RNA-therapy-for-hemophilia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":71,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,11,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022018661","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}